Stock Story: Stryker
July 2024
Stryker Corporation: transforming patient care for over 150 million patients annually.
Innovation leadership is a key hallmark of a high-quality business. When we think about major innovation trends globally, the most prominent headlines usually spotlight the technology sector.
Recent excitement about artificial intelligence and its many applications is a prime example. However, less visible yet equally transformative is the pace of innovation in a sector often considered more constant: healthcare.
The pace of healthcare innovations has accelerated dramatically in recent decades, leading to significant advancements in healthcare services and improving quality of life. For instance, the world witnessed the rapid development of the mRNA vaccine platform, which played a crucial role in combating the covid-19 pandemic. Additionally, new GLP-1 agonists are showing potential in addressing the growing global obesity epidemic.
The healthcare subsector of medical devices stands out as a vital contributor to enhanced medical treatments. This is due primarily to the adoption of new and innovative medical technologies by physicians and health systems worldwide. These technologies have been clinically proven to deliver superior patient outcomes, improved surgical techniques, and operating room efficiencies.
A standout leader in the medical devices subsector is Stryker Corporation. With a diverse product portfolio spanning orthopaedics, medical and surgical equipment, and neurotechnology, Stryker's products are available in over 75 countries, affecting more than 150 million patients annually. If you have ever been treated in an operating room in a hospital, chances are you encountered one or more of Stryker's products.
"Mako Robotic procedures result in meaningfully
higher patient satisfaction rates..."
Stryker's journey began in Michigan, USA, in 1941, founded by a prominent orthopaedic surgeon and medical device inventor Dr Homer Stryker – which is fitting given the company has been at the forefront of medical innovation in the orthopaedic surgical category over the past decade. Beyond continuous enhancements in knee and hip implant designs, such as cementless designs that better promote bone growth, Stryker revolutionised the field in 2017 with its Mako Robotic-Arm, assisting surgeons in performing knee and hip replacements with unprecedented precision.
Clinical studies highlight that Mako Robotic procedures result in meaningfully higher patient satisfaction rates, with lower post-operative pain, faster recovery times, more accurate bone resections and implant placement and reduced soft tissue damage. This has accelerated surgeon adoption, with over 60% of knee and 30% of hip implants sold by Stryker in the US now implanted using a Mako Robot.
Despite significant investments by competitors in R&D, they have struggled to dethrone Stryker's leadership. This underscores Stryker's R&D strength, driven by its unique 'bottom-up' capital allocation model and the 'innovation flywheel' effect stemming from long-standing relationships with leading surgeons and teaching hospitals. Stryker holds over 5,000 patents, 400 of which are in its digital robotics platform – a ten-fold increase in the past decade. Plans are underway to extend the Mako Robot to new surgical indications, including upper extremities (shoulder) and spine.
Stryker's innovation is not limited to orthopaedics. The company is advancing surgical planning and navigational software for cranial and spine procedures with its Q Guidance System and improving surgical visualisation and fluorescence imaging for minimally invasive surgeries with its 1788 platform. The growing installed base of Stryker's systems, alongside the lack of superior alternatives from competitors, underscores the impressive nature of its advancements.
Importantly, impactful innovation can lead to pricing power through a combination of patient/physician preferences and patent protection, and higher switching costs due to the invasive nature of surgical products and the growing clinical evidence of improved patient outcomes. This gives us confidence in Stryker's above-peer growth outlook, which is particularly bolstered by its ability to benefit three key stakeholders in health systems worldwide where expenditure continues to reach new heights: patients, surgeons, and hospitals.
By Wilson Nghe, Investment Analyst
Sources: Company filings.
Important Information: This material is not intended to constitute advertising or advice of any kind and you should not construe the contents of this material as legal, tax, investment or other advice. In making an investment decision, you should read and consider any relevant offer documentation applicable to any investment product or service and must rely on your own examination of the same and consider obtaining professional investment advice tailored to your specific circumstances before making any investment decision.
The investment program of the strategy or strategies presented herein (‘Strategy’) is speculative and may involve a high degree of risk. The Strategy is not intended as a complete investment program and is suitable only for sophisticated investors who can bear the risk of loss. The Strategy may lack diversification, which can increase the risk of loss to investors. The Strategy’s performance may be volatile. Past performance is not necessarily indicative of future results and no person guarantees the future performance of the Strategy, the amount or timing of any return from it, that asset allocations will be met, that it will be able to implement its investment strategy or that its investment objectives will be achieved. Statements contained in this material that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs and such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. This material may contain ‘forward-looking statements’. Actual events or results or the actual performance of the Strategy or any financial product or service may differ materially from those reflected or contemplated in such forward-looking statements. The Strategy will have limited liquidity, no secondary market for interests in the Strategy is expected to develop and there are restrictions on an investor’s ability to withdraw and transfer interests in the Strategy. The management fees, incentive fees and allocation and other expenses of the Strategy will reduce trading profits, if any, or increase losses.
No representation or warranty is made with respect to the correctness, accuracy, reasonableness or completeness of any of the information contained in this material. This information is subject to change at any time and no person has any responsibility to update any of the information provided in this material. This material may include data, research and other information from third party sources. No guarantee is made that such information is accurate, complete or timely and no warranty is given regarding results obtained from its use. The issuer of this material and its related entities and affiliates will not be responsible or liable for any losses, whether direct, indirect or consequential, including loss of profits, damages, costs, claims or expenses, relating to or arising from your use or reliance upon any part of the information contained in this material including trading losses, loss of opportunity or incidental or punitive damages.
This material and the information contained within it may not be reproduced, or disclosed, in whole or in part in any circumstances. , Further information regarding any benchmark referred to herein can be found at www.magellaninvestmentpartners.com/funds/benchmark-information/. Any third-party trademarks contained herein are the property of their respective owners and are used for information purposes and only to identify the company names or brands of their respective owners. (080825-#i1)
United Kingdom: This material has been prepared by Magellan Asset Management Limited (ABN 31 120 593 946 AFSL 304 301) doing business as Magellan Investment Partners and is distributed in the United Kingdom by Magellan Investment Partners (UK) Limited (FRN: 1037936), an appointed representative of Sentinel Regulatory Services Ltd (FRN: 1007093) which is authorised and regulated by the Financial Conduct Authority. This material does not constitute an offer or inducement to engage in an investment activity under the provisions of the Financial Services and Markets Act 2000 (FSMA). This material does not form part of any offer or invitation to purchase, sell or subscribe for, or any solicitation of any such offer to purchase, sell or subscribe for, any shares, units or other type of investment product or service. This material or any part of it, or the fact of its distribution, is for background purposes only. This material has not been approved by a person authorised under the FSMA and its distribution in the United Kingdom and is only being made to persons in circumstances that will not constitute a financial promotion for the purposes of section 21 of the FSMA as a result of an exemption contained in the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (FPO) as set out below. This material is exempt from the restrictions in the FSMA as it is to be strictly communicated only to ‘investment professionals’ as defined in Article 19(5) of the FPO.
United States: This material has been prepared by Magellan Asset Management Limited (ABN 31 120 593 946 AFSL 304 301) doing business as Magellan Investment Partners (‘Magellan’) which is a registered investment adviser. The investment strategies described herein are distributed in the United States by Frontier Partners, Inc. (‘Frontier’), a U.S.-registered investment adviser. For the purposes of the US Securities Act 1933, Magellan and Frontier are affiliated entities. Registration as an investment adviser does not imply any level of skill or training. This material is not intended as an offer or solicitation for the purchase or sale of any securities, financial instrument or product or to provide financial services. It is not the intention of Magellan to create legal relations on the basis of information provided herein. Past performance does not guarantee future results. Where performance figures are shown net of fees charged to clients, the performance has been reduced by the amount of the highest fee charged to any client employing that particular strategy during the period under consideration. Actual fees may vary depending on, among other things, the applicable fee schedule and portfolio size. Fees are available upon request and also may be found in Part II of Magellan’s Form ADV.
Canada: This material is provided to you by Magellan Asset Management Limited (ABN 31 120 593 946 AFSL 304 301) doing business as Magellan Investment Partners (‘Magellan’). Magellan is not registered in any province in Canada. The head office of Magellan is in Sydney, Australia and all or substantially all of its assets are situated outside of Canada. Due to the foregoing, there may be difficulty enforcing legal rights against Magellan.
South Africa: This material is provided to you by Magellan Asset Management Limited (ABN 31 120 593 946 AFSL 304 301) doing business as Magellan Investment Partners, who in accordance with FAIS Notice 55 of 2023 issued by the Financial Sector Conduct Authority, Magellan Investment Partners is exempted from section 7(1) of the Financial Advisory and Intermediary Services Act, 2002 (Act No. 37 of 2002). This material is not an offer in terms of Chapter 4 of the Companies Act, 2008.
UAE: This material has been produced by Magellan Asset Management Limited (ABN 31 120 593 946 AFSL 304 301) doing business as Magellan Investment Partners. This material is not for distribution to any other person. This material, and the information contained herein, does not constitute, and is not intended to constitute, a public offer of securities in the United Arab Emirates (‘UAE’) and accordingly should not be construed as such. Any offer of securities or financial services is made only to a limited number of exempt Professional Investors in the UAE who fall under one of the following categories: federal or local governments, government institutions and agencies, or companies wholly owned by any of them. No securities or services have been approved by or licensed or registered with the UAE Central Bank, the Securities and Commodities Authority, the Dubai Financial Services Authority, the Financial Services Regulatory Authority or any other relevant licensing authorities or governmental agencies in the UAE (the ‘Authorities’). The Authorities assume no liability for any investment that the named addressee makes as a Professional Investor. This material is for the use of the named addressee only and should not be given or shown to any other person (other than employees, agents or consultants in connection with the addressee’s consideration thereof). Other jurisdictions: This material is provided to you by Magellan Asset Management Limited (ABN 31 120 593 946 AFSL 304 301) doing business as Magellan Investment Partners.
No distribution of this material will be made in any jurisdiction where such distribution is not authorised or is unlawful. This material does not constitute, and may not be used for the purpose of, an offer or solicitation in any jurisdiction or in any circumstances in which such an offer or solicitation is unlawful or not authorized or in which the person making such offer or solicitation is not qualified to do so. (080825-#W17)